09/12/2025
APC are proud to play a part in the ProstACT Global Phase 3 trial - an important milestone in advancing prostate cancer therapy.
The first patient has been dosed in Part 2 (randomized treatment expansion) of Telix’s Phase 3 ProstACT Global study evaluating our lead prostate cancer therapy candidate, TLX591, in patients with metastatic castration-resistant prostate cancer (mCRPC).
The patient was dosed at the Australian Prostate Centre in Melbourne, Australia. This is an important milestone in this innovative trial – which is the first Phase 3 trial to combine TLX591 with Standard of Care (SOC; abiraterone, enzalutamide or docetaxel) versus SOC alone.
Part 2 of ProstACT Global will enroll approximately 490 patients and is currently recruiting in Australia, New Zealand and Canada, with further expansion approved across China, Singapore, South Korea, Türkiye and the United Kingdom.
Read more on our website here: https://telixpharma.com/news-views/prostact-global-phase-3-update-first-patient-dosed-in-randomized-treatment-expansion-part-1-readout-plans-confirmed/
TLX591 has not received a marketing authorization in any jurisdiction.